Novel Application of the Two‐Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin

Ertugliflozin, a sodium glucose cotransporter‐2 inhibitor, is approved in the United States for treatment of type 2 diabetes mellitus. A novel two‐period study design with (14)C microtracer dosing in each period was used to determine absolute oral bioavailability (F) and fraction absorbed (F(a)) of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Transl Sci
Main Authors: Raje, Sangeeta, Callegari, Ernesto, Sahasrabudhe, Vaishali, Vaz, Alfin, Shi, Haihong, Fluhler, Eric, Woolf, Eric J., Schildknegt, Klaas, Matschke, Kyle, Alvey, Christine, Zhou, Susan, Papadopoulos, Dimitris, Fountaine, Robert, Saur, Didier, Terra, Steven G., Stevens, Lloyd, Gaunt, Daniel, Cutler, David L.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6039199/
https://ncbi.nlm.nih.gov/pubmed/29575530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.12549
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados